Tibulizumab Systemic Sclerosis Understanding and Response Evaluation

על הניסוי

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

צפו ב-NCT06843239 ב-ClinicalTrials.gov ←

קישורים קשורים